• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Transcreener Assay Used to Evaluate PI3K Inhibitors

by Bellbrook Labs / Tuesday, 17 March 2020 / Published in Success Stories
PI3K Inhibitors for Cancer Research

PI3K Inhibitors and Cancer – Although cancer is widespread, determining the culprit, as well as individual treatment, is challenging. A variety of cancer types exist with a multitude of contributors. Being the most common human genetic disease, a whole host of genes are involved. Some contribute to curbing cancer (tumor suppressor genes), while oncogenes promote it. Many of these genes and their specific role in cancer have been identified. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3Kα) is one of the most frequently mutated oncogenes in cancer with mutations often found in patients with breast cancer.2  In fact, double PI3Kα mutations where two different mutations are found in one allele occur frequently in breast cancers among other cancers.

Oncogenic mutations can lead to the gene being constitutively activated.3 With the range of important functions that PI3Kα has a hand in including cell growth, migration, material transport, cell survival, and production of new proteins, it’s no wonder how mutated versions of the gene lead to cancer. It does this by encoding for the catalytic subunit of phosphoinositide 3-kinase (PI3K); p110 alpha (p110α) protein. PI3K phosphorylates signaling molecules triggering a series of downstream reactions that allow for the aforementioned functions.3

Discovering Benefits of PI3K Inhibitors

PI3Kα  inhibitors such as alpelisib have been on the market as a treatment for hormone receptor-positive breast cancer with mutations in PI3Kα. Researchers from a large group including Memorial Sloan Kettering Cancer Center recently published a paper on these findings in Science. Aided by the Transcreener® ADP² Kinase Assay recently identified cancers with double PI3Kα mutations specific to the cis region of the gene compared to the trans region are even more sensitive to PI3Ka inhibitors.3 Linking individual genetics in this way is a powerful means of therapy with the added benefit of specificity.

The scientists used the Transcreener Assay to determine IC50 values for PI3K inhibitors with recombinant PI3Kα.3 The ability of PI3Kα to transfer a phosphate from ATP to another molecule (or substrate), forming ADP as a product was measured via fluorescence intensity (FI). More product increases the FI as the tracer and quencher move further in proximity.  The reaction contains a quenched ADP Alexa Fluor® 594 tracer bound to an ADP antibody conjugated to an IRDye® QC-1 quencher. Making the assay unique, it detects the activity of most kinases including serine/threonine protein kinases both as an endpoint or continuous assay.

The discovery is exciting news for those interested in pharmacogenetics and especially those suffering from breast cancer. Moreover, it’s an ideal way to utilize the Transcreener ADP² Assay.

References

  1. Note, T. (n.d.). Transcreener® ADP² Fluorescence Intensity Assay Implementation on Tecan’s Infinite 200 Multimode Reader Series, (2), 1–4. http://www.neotec.co.il/wp-content/uploads/2014/03/TN-Inf200Transcreener-FI_V1.0.pdf
  2. Toker, A. (2019). Double trouble for cancer gene. Science, 366(6466), 685–686. https://doi.org/10.1126/science.aaz4016
  3. Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., … Baselga, J. (2019). Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors. Science, 366(6466), 714–723. https://doi.org/10.1126/science.aaw9032
Tagged under: kinase assay, PIK3, Transcreener ADP Kinase Assay

What you can read next

Performing an ATPase Enzyme Assay
Researchers Use ATPase Enzyme Assay to Study SMCHD1 Mutations
RIPK1 Inhibitors Inflammatory disease treatment
Transcreener ADP Assay Used to Discover RIPK1 Inhibitors
Researchers Studying Hsp70 Activity
Researchers Validate Hsp70 Activity with the Transcreener ATPase Assay

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...
  • Webinar Graphic

    Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

    The immune system uses the recognition of forei...
  • Lab IRAK4 Inhibitors Kinase Assay Kit

    Uncovering IRAK4 Inhibitors with a Transcreener Kinase Assay Kit

    Genentech discovers IRAK4 inhibitors using the ...
  • Assay Development Services - Two Scientists Working In the Lab

    Five Considerations When Choosing a Biochemical Assay Development Services CRO

    There are many options out there for choosing a...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP